FDA Approves RedHill's COVID-19 Clinical Study With Opaganib; Stock Up 9%

Shares of RedHill Biopharma Ltd. (RDHL) are moving up over 9% in pre-market today, after the company announced that the U.S. FDA has approved its Investigational New Drug or IND application for a Phase 2a clinical study evaluating its investigational drug, opaganib, in patients with confirmed moderate-to-severe SARS-CoV-2 infection, the cause of COVID-19.

from RTT - Before the Bell https://ift.tt/3dtiqU8
via IFTTT